Almirall Prodesfarma S.a.

Laboratorios Almirall, S.a.

Almirall, S.a.

Jordi Gracia Ferrer

Bernat Vidal Juan

José Manuel Prieto Soto

Vittorio Dal Piaz

Armando Vega Noverola

Maria Antonia Buil Albero

Joan Taltavull Moll

Nuria Aguilar Izquierdo

Claudia Vergelli

Maria Paola Giovannoni

Marta Carrascal Riera

Yolanda Garrido Rubio

Lluis Miquel Pages Santacana

Wenceslao Lumeras Amador

Juan Francisco Caturla Javaloyes

Montserrat Erra Sola

Victor Giulio Matassa

Cristina Esteve Trias

Emma Terricabras Belart

Joan Feixas Gras

Francisco Javier Bernal Anchuela

Antonia Maria Buil Albero

Ma Isabel Crespo Crespo

New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks). 

Pyrrolotriazinone derivatives as inhibitors P13K

The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives of Formula (I) and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and are thus useful in the treatment, prevention or suppression of pathological conditions, diseases and disorders known to be susceptible of being improved by inhibition of PDE4 such as asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis or irritable bowel disease. 

[object Object]

New pyridazin-e-(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4. 

Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors

Pyridazin-3(2H)-one derivatives of formula (I) are found to inhibit PDE-4. R, Rand Rare organic radicals, Ris a cyclic group, and Ris an ester or an aryl or heteroaryl group. 

Pyridazin-3(2H)-one derivatives

This invention relates to new therapeutically useful 8-(disubstituted)phenyl-6,9-dihydro-5H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-c]pyrimidine-5-one and 8-phenyl-6,9-dihydro-5H-pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine-5-one derivatives of formula (I): wherein: &#x2014;X&#x2014;C&#x2014;Y&#x2014; represents (a) or (b) to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their medical uses as potent and selective inhibitors of phosphodiesterase 5 (PDE 5).

Pyrrolotriazolopyrimidinone derivatives

8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives of formula (I):or a pharmaceutically acceptable salt thereof processes for their preparation, pharmaceutical compositions containing them and their use as PDE 5 inhibitors.

8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives

The invention relates to new 6-phenylpyrrolopyrimidine derivatives of formula (I):wherein: &#x2014;X&#x2014;C&#x2014;Y&#x2014; represents

6-phenylpyrrolopyrimidinedione derivatives

1,2,4-triazolo(4,3-b)pyrido(3,2-d)pyridazine derivatives and pharmaceutical compositions containing them

Growing community of inventors

Barcelona, Spain

Jordi Gracia Ferrer